About the Company

[Summary] 致力于促进基于结构药理学的治疗创新

南京红云生物科技有限公司是通过基于的结构药理学的药物设计技术平台,针对肿瘤耐药靶点(或first in 靶点)研发创新小分子药物的一家公司。结构药理学专注于应用结构生物学研究手段从亚分子水平和微观三维空间的角度对药物作用于靶点的原理进行深入研究,也称为结构分子药理学。结构药理学辅助药物设计是近年来结构生物学应用于新药研发的新突破。此技术首先运用结构生物学和蛋白质化学手段设计和表达临床上导致肿瘤耐药的蛋白,再将蛋白与已知可结合的分子制备成复合物,通过冷冻电镜或X-射线单晶衍射技术直接测定该复合的真实三维结构,在此三维结构的基础上直观地进行药物设计,从而获得药物先导化合物。

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

红云生物 Financing History (3 rounds)

Manage
B+轮
Capital Market Favor
Latest Financing Round
  • Date: ?
  • Amount: 近亿人民币
  • Investor: 荷塘创投,仁金投资,夏尔巴...

红云生物 honors, qualifications & industry associations

Tags are labelled based on keyword text matching analysis and may be related to the company. For reference only.

红云生物 Related Industry Tags

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 1,009.9272万(元)
Legal Representative: 黄鑫
Date Established:
Credit Code: 91320115MA1WMM4J9X
Registered Address: 江苏省泰州市医药高新技术产业开发区解家舍路2号6号楼410室

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates